By Nono Hu, Director of Marketing, LSN
With 10 days to go until the first RESI San Diego event, LSN is proud to present the latest RESI program guide. If you want to see the full lineup of sponsors, investor panelists, RESI Innovators and speakers, you’re in the right place. RESI San Diego will bring together hundreds of active investors and early stage startups to begin their BIO week with a dedicated day of partnering, networking, and early stage-focused content. Check out the details below.
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series
Life Science Nation (LSN) and Johnson and Johnson Innovation, JLABS have launched San Diego’s first Redefining Early Stage Investments (RESI) Conference on June 19th, 2017 during the 2017 BIO week when the biotech and medtech world gathers in San Diego. RESI San Diego will bring together 400+ fundraising CEOs and 400+ early stage investors (a 1:1 ratio) from around the globe, providing the opportunity for dialogue and relationship building, with the goal of eventual capital allocations. Register for RESI now.
By Lucy Parkinson, Director of Research, LSN
RESI is a venue where early stage life science startups can meet with investors of every type that are a fit for their company’s technology and stage – and that includes family offices. RESI San Diego features two panels devoted to this elusive investor class – Biotech Family Offices and Medtech Family Offices. Whether you’re developing a novel therapeutic, an innovative device or an improved diagnostic solution, Family Offices can’t be overlooked as a potential source of capital and RESI will provide you with the opportunity to hear advice and insight directly from key investment decision makers from family offices.
Biotech Family Offices, moderated by Colin Widen (CEO, Boston Innovation Capital), features:
Medtech Family Offices, moderated by Michael Quigley (VP of Market Research, Life Science Nation), features:
To catch this rare opportunity to meet family office investors with a focus on early stage life science investment, register for RESI now.
A large conglomerate headquartered in China has a primary business in single-use medical devices, with a wide range of product lines in consumables, orthopedic materials, and blood purification. The group also has subsidiaries in biopharmaceutical, healthcare services, finance, and real estate. The firm is actively expanding its healthcare business in China. The group is seeking product-based collaboration opportunities with early stage medical device businesses overseas, primarily through joint venture or incubation. Typical investments range from RMB 1-30 million (US$0.1 – 4.4 M), while there is no set upper limit. The firm would also consider in-licensing opportunities.
The firm is focusing on medical devices with an elevated interest in coronary stent, vascular ultrasound, endoscope, and surgical devices. The firm is also interested in medical technologies that are complimentary to its product line, which includes: i) consumables (infusion sets, syringes, medical needles, blood bags, pre-filled syringes, blood sampling products, and other consumables); ii) orthopedic materials and iii) blood purification consumables and equipment. The group prefers products that have received FDA clearance/approval or at early commercial stage, while it is also open to projects that are pending an FDA decision. The group would also consider biopharmaceutical assets in kidney diseases.
The firm is seeking strong management teams with mature products that have received or are close to receiving regulatory approval.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
A global biotech company headquartered in France is actively seeking to expand its pipeline by working with early stage biotechs and academic groups. The company is open to a variety of deal structures and seeks to construct deals that maximize the potential of the therapeutic program.
The firm is focused on oncology, rare disease, and select neuroscience drug assets. The firm is interested in highly differentiated late stage pre-clinical and clinical stage therapeutic candidates with strong scientific rationale targeting indications with significant unmet medical need.
The firm has no strict requirements for companies or management teams and looks to work creatively and collaboratively on partnerships with early-stage companies. The firm is open to opportunities/companies on a global basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
A private equity fund headquartered in Shanghai, China, was initiated through a partnership between two strategic firms. The fund mainly focuses pharmaceuticals, medical device & diagnostic, and healthcare services. The firm typically makes equity investments of US$5-10 million per deal over a 5-6 year exit horizon. The firm is open to leading or co-investing. The firm is investing from its RMB and USD funds and is currently seeking opportunities from China and the U.S.
The firm has a clearly defined investment focus primarily on three healthcare subsectors: Pharmaceuticals, Medical Device & Diagnostic, and Medical Service. Within pharmaceuticals, the firm considers chemical drugs in Oncology, Cardiovascular, Gastrointestinal, second generation drugs, brand generics, OTC, drug delivery platforms, CRO/CMO; and biotech products in Biosimilar, Vaccines, blood products, etc. The firm prefers first-in-class projects in phase I or IIa with safety and efficacy data. Within Medical Device and Diagnostics, the firm is interested in High-end devices, Consumables, Implantable Devices and Interventional Devices with high-technical barrier, Molecular Diagnostics, Immunological Diagnostics, and Genetic Diagnostics. The firm is especially interested in medical robotics and AI. In addition, the firm would consider R&D services that support cell therapy, stem cell, and new therapies. For 505b2 drugs or medical devices, the firm considers from preclinical to pre-IND stages.
The firm is looking for experienced management teams with sector expertise. Within China, the firm prefers company with approved products and sales track record. Within the U.S., the firm can consider earlier stage companies depending on the business model and exit strategy. The firm’s GP has strong network in China and can offer assistance in distribution and registration.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
A VC investment group founded by a pharmaceutical firm has offices in China and California, and currently manages a fund of over $50 million. The firm typically invests $500K-$1M per company with the ability to make acquisitions via its parent company of up to $100M. The firm is seeking companies globally with innovative technologies to bring to the China market, and supports FDA-approved companies to gain CFDA approval.
The firm is open to all types of medical device, diagnostic, and healthcare technology. The firm is not interested in pharmaceuticals or biotech therapeutics due to the longer development timeline, and particularly seeks late-stage technologies that are near or on-the-market generating revenue. The firm is open to all classes of devices. The firm will only look at technology that is close to FDA clearance, within 5 years of return, and has at least developed and tested a prototype with preclinical data. The firm has historically been interested in women’s health indications; women and children health-related products or services; life science-related products to be used in the research field; diagnostic kits; and immunotherapy and cell therapy services.
The firm is seeking to invest or acquire private companies. Companies with products to be introduced to China is preferred.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
